• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BiomX Inc. (Amendment)

    2/13/24 1:09:20 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    SC 13G/A 1 formsc13ga.htm FORM SC 13G/A MMCAP International Inc. SPC: Form SC 13G/A - Filed by newsfilecorp.com

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)

    BiomX Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    09090D103

    (CUSIP Number)


    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

    Check the Appropriate box to designate the rule pursuant to which this schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     


    CUSIP No. 09090D103

     

    Page 2 of 6 Pages


    1 NAME OF REPORTING PERSONS
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

     
      MMCAP International Inc. SPC

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☒
    (b) ☐
                


    3 SEC USE ONLY  
                


    4 CITIZENSHIP OR PLACE OF ORGANIZATION  
      Cayman Islands

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5 SOLE VOTING POWER
     
    0
    6 SHARED VOTING POWER
     
    1,527,994*
    7 SOLE DISPOSITIVE POWER
     
    0
    8 SHARED DISPOSITIVE POWER
     
    1,527,994*
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
      1,527,994*

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ☐
                


    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
      3.22%**

     
    12 TYPE OF REPORTING PERSON  
      CO

     

    FOOTNOTES

    * Consists of 96,805 shares of the Issuer’s common stock and warrants to acquire an additional 1,431,189 shares of common stock.

    ** The percentages used herein are calculated based on 45,979,930 shares of common stock outstanding of the Issuer as reported in the Form S-3 Registration Statement filed with the Securities and Exchange Commission on December 28, 2023, plus 1,431,189 shares underlying warrants which are beneficially owned by the reporting persons and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.



    CUSIP No. 09090D103

     

    Page 3 of 6 Pages


    1 NAME OF REPORTING PERSONS
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS

     
      MM Asset Management Inc.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ☒
    (b) ☐
                


    3 SEC USE ONLY  
                


    4 CITIZENSHIP OR PLACE OF ORGANIZATION  
      Ontario, Canada

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5 SOLE VOTING POWER
     
    0
    6 SHARED VOTING POWER
     
    1,527,994*
    7 SOLE DISPOSITIVE POWER
     
    0
    8 SHARED DISPOSITIVE POWER
     
    1,527,994*
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
      1,527,994*

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ☐
                


    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
      3.22%**

     
    12 TYPE OF REPORTING PERSON  
      CO

     

    FOOTNOTES

    * Consists of 96,805 shares of the Issuer’s common stock and warrants to acquire an additional 1,431,189 shares of common stock.

    ** The percentages used herein are calculated based on 45,979,930 shares of common stock outstanding of the Issuer as reported in the Form S-3 Registration Statement filed with the Securities and Exchange Commission on December 28, 2023, plus 1,431,189 shares underlying warrants which are beneficially owned by the reporting persons and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.



    CUSIP No. 09090D103

     

    Page 4 of 6 Pages

    Item 1 (a). Name of Issuer:

    BiomX Inc.

    Item 1 (b). Address of Issuer's Principal Executive Offices:

    22 Einstein St., 5th Floor, Ness Ziona, Israel, 7414003

    Item 2 (a). Name of Person Filing:

    i) MMCAP International Inc. SPC

    ii) MM Asset Management Inc.

    Item 2 (b). Address of Principal Business Office or, if None, Residence:

    i) c/o Mourant Governance Services (Cayman) Limited
    94 Solaris Avenue
    Camana Bay, P.O. Box 1348
    Grand Cayman, KY1-1108, Cayman Islands

    ii) 161 Bay Street
    TD Canada Trust Tower Suite 2240
    Toronto, ON M5J 2S1 Canada

    Item 2 (c). Citizenship:

    i) Cayman Islands
    ii) Ontario, Canada

    Item 2 (d). Title of Class of Securities:

    Common Stock, $0.0001 par value

    Item 2 (e). CUSIP Number:

    09090D103

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     (a) ☐ Broker or dealer registered under Section 15 of the Act;

     (b) ☐ Bank as defined in Section 3(a)(6) of the Act;

     (c) ☐ Insurance Company as defined in Section 3(a)(19) of the Act;

     (d) ☐ Investment Company registered under Section 8 of the Investment Company Act;

     (e) ☐ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     (f) ☐ Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);

     (g) ☐ Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);

     (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;


    CUSIP No. 09090D103

     

    Page 5 of 6 Pages

     (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940:

     (j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(j).

     ☒ If this statement is filed pursuant to Rule 13d-1(c), check this box.

    Item 4. Ownership.

     Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.

     (a) Amount beneficially owned: 1,527,994*

     (b) Percent of class:  3.22%**

     (c) Number of shares as to which such person has:

     (i) Sole power to vote or to direct the vote:  0

     (ii) Shared power to vote or to direct the vote:  1,527,994*

     (iii) Sole power to dispose or to direct the disposition of:  0

     (iv) Shared power to dispose or to direct the disposition of:  1,527,994*

    * Consists of 96,805 shares of the Issuer's common stock and warrants to acquire an additional 1,431,189 shares of common stock.

    ** The percentages used herein are calculated based on 45,979,930 shares of common stock outstanding of the Issuer as reported in the Form S-3 Registration Statement filed with the Securities and Exchange Commission on December 28, 2023, plus 1,431,189 shares underlying warrants which are beneficially owned by the reporting persons and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.

    Instruction.  For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

    Item 5. Ownership of Five Percent or Less of a Class.

    If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     N/A

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     N/A

    Item 8. Identification and Classification of Members of the Group.

     N/A

    Item 9. Notice of Dissolution of Group.

     N/A


    CUSIP No. 09090D103

     

    Page 6 of 6 Pages

    Item 10.       Certification.  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      MMCAP International Inc. SPC
       
    Date: February 13, 2024 By: /s/ Ulla Vestergaard                                      
     
            Name: Ulla Vestergaard
          Title: Director
       
     
     
     
     
       
      MM Asset Management Inc.
       
    Date: February 13, 2024 By: /s/ Hillel Meltz                                                  
     
            Name: Hillel Meltz
          Title: President


    Get the next $PHGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by BiomX Inc.

    SCHEDULE 13D/A - BiomX Inc. (0001739174) (Subject)

    2/11/26 7:24:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    2/10/26 4:29:14 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by BiomX Inc.

    S-3 - BiomX Inc. (0001739174) (Filer)

    2/9/26 4:33:55 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX Issues Statement Regarding Recent Common Stock Trading Activity

    NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock. NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement

    1/27/26 1:41:26 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

    Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial  BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) --  BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced its discontinuation of the ongoing Phase

    12/8/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yeganeh Reuven

    3 - BiomX Inc. (0001739174) (Issuer)

    1/16/26 7:59:12 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by *Director by Deputization Flynn James E

    4 - BiomX Inc. (0001739174) (Issuer)

    4/23/25 5:49:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by Director Merril Gregory Louis

    4/A - BiomX Inc. (0001739174) (Issuer)

    4/21/25 8:24:29 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

    11/16/21 9:23:03 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

    10/19/21 8:36:54 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on BiomX with a new price target

    HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

    10/18/21 12:27:44 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Announces the Appointment of Susan Blum to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

    4/18/24 8:00:00 AM ET
    $PHGE
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Telum Therapeutics appoints Dr. Subhendu Basu as CEO

    Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

    3/19/24 5:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

    10/18/23 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Financials

    Live finance-specific insights

    View All

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

    Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success  BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZIONA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specif

    11/12/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

    NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its third quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and a live audio webcast at 8:30 a.m. ET, to discuss the third quarter of 2025 financial results and provide program updates. To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the sta

    11/5/25 8:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care